Mylan Pharmaceuticals received FDA approval for a transdermal estradiol patch, a move likely to intensify competitive pricing pressures and potentially erode the market share of branded hormone replacement therapy products. This regulatory clearance allows Mylan to offer a lower-cost alternative to existing players in the transdermal hormone delivery space.